<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02316886</url>
  </required_header>
  <id_info>
    <org_study_id>AMCCV2014-13</org_study_id>
    <nct_id>NCT02316886</nct_id>
  </id_info>
  <brief_title>The Preventive Coronary Intervention on Stenosis With Functionally Insignificant Vulnerable Plaque</brief_title>
  <acronym>PREVENT</acronym>
  <official_title>The Preventive Coronary Intervention on Stenosis With Functionally Insignificant Stenosis With Vulnerable Plaque Characteristics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Jung Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether preventive coronary intervention on
      functionally insignificant coronary stenosis with vulnerable plaque characteristics plus
      optimal medical therapy reduces the incidence of the composite of cardiovascular death,
      target vessel myocardial infarction, or ischemia driven target lesion revascularization
      compared with optimal medical therapy alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sub-analysis for each imaging test will be performed as below ;

        -  NIRS(Near-infrared spectroscopy)

        -  OCT(Optical coherence tomography)

        -  VH-IVUS(IVUS-derived virtual histology)

        -  IVUS(Intravascular ultrasonography)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target vessel failure</measure>
    <time_frame>2 years</time_frame>
    <description>Target vessel failure (TVF) is defined as a composite of cardiac death, target vessel related MI, ischemia-driven target vessel revascularization, or unplanned hospitalization for angina.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac event</measure>
    <time_frame>2 years</time_frame>
    <description>defined as cardiovascular death, nonfatal myocardial infarction, or unplanned rehospitalization due to unstable angina</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure, defined as a composite of cardiovascular death, target lesion related myocardial infarction, or target lesion revascularization</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death from any causes</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The composite of death, myocardial infarction, and any repeat revascularization</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>2 years</time_frame>
    <description>Cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel-related myocardial infarction</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death and combinations of cardiac death with other components of MACE</measure>
    <time_frame>1 month</time_frame>
    <description>Cardiac death and combinations of cardiac death with other components of MACE at each time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death and combinations of cardiac death with other components of MACE</measure>
    <time_frame>6 months</time_frame>
    <description>Cardiac death and combinations of cardiac death with other components of MACE at each time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death and combinations of cardiac death with other components of MACE</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiac death and combinations of cardiac death with other components of MACE at each time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death and combinations of cardiac death with other components of MACE</measure>
    <time_frame>2 years</time_frame>
    <description>Cardiac death and combinations of cardiac death with other components of MACE at each time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-urgent revascularization procedures</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned hospitalization for angina</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCS(Canadian Cardiovascular Society) angina class</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of anti-anginal medication</measure>
    <time_frame>1 month</time_frame>
    <description>Number of anti-anginal medication at each point in time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of anti-anginal medication</measure>
    <time_frame>6 months</time_frame>
    <description>Number of anti-anginal medication at each point in time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of anti-anginal medication</measure>
    <time_frame>12 months</time_frame>
    <description>Number of anti-anginal medication at each point in time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of anti-anginal medication</measure>
    <time_frame>2 years</time_frame>
    <description>Number of anti-anginal medication at each point in time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of non-urgent (repeat) revascularization</measure>
    <time_frame>1 month</time_frame>
    <description>Rate of non-urgent (repeat) revascularization at each point in time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of non-urgent (repeat) revascularization</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of non-urgent (repeat) revascularization at each point in time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of non-urgent (repeat) revascularization</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of non-urgent (repeat) revascularization at each point in time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of non-urgent (repeat) revascularization</measure>
    <time_frame>2-year</time_frame>
    <description>Rate of non-urgent (repeat) revascularization at each point in time</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Plaque, Atherosclerotic</condition>
  <arm_group>
    <arm_group_label>Coronary intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bioresorbable Vascular Scaffold or Everolimus Eluting stent (EES) +Optimal Medical Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal Medical Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Optimal Medical Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Coronary intervention</intervention_name>
    <description>Bioresorbable Vascular Scaffold or Everolimus Eluting stent (EES) +Optimal Medical Treatment</description>
    <arm_group_label>Coronary intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optimal Medical treatment</intervention_name>
    <arm_group_label>Optimal Medical Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Symptomatic or asymptomatic coronary artery disease patients

          -  Patients having at least one significant stenosis (diameter stenosis &gt; 50%) with FFR
             &gt;0.80 and meeting two of the following:

               1. MLA(minimal luminal area)&lt;4mm2

               2. plaque burden&gt;70%

               3. Lipid-rich plaque on NIRS(Intracoronary Near-Infrared Spectroscopy) (defined as
                  maxLCBI4mm&gt;315)

               4. TCFA(thin-cap fibroatheroma) defined by OCT(fibrous cap thickness&lt;65µm and
                  arc&gt;90°) or VH-IVUS≥10% confluent NC with&gt;30° abutting to the lumen in 3
                  consecutive slices)

                    -  2 target vulnerable lesions

          -  Eligible for percutaneous coronary intervention with Absorb Bioresorbable Vascular
             Scaffold or Everolimus Eluting Stent

          -  Willing and able to provide informed written consent

          -  Reference vessel diameter 2.75-4.0

          -  Lesion length ≤ 40

        Exclusion Criteria:

          -  Patients in whom the preferred treatment is CABG(Coronary artery bypass grafting)

          -  Stented lesion

          -  Bypass graft lesion

          -  The patients who have more than or equal to 3 target lesions

          -  2 target lesions in the same coronary territory

          -  Heavily calcified or angulated lesion

          -  Bifurcation lesion requiring 2 stenting technique

          -  Contraindication to or planned discontinuation of dual antiplatelet therapy within 1
             year

          -  Life expectancy less than 2 years

          -  Planned cardiac surgery or planned major non cardiac surgery

          -  Woman who are breastfeeding, pregnant or planning to become pregnant during the course
             of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregg Stone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jung-Min Ahn, MD</last_name>
    <email>drjmahn@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jung-Hee Ham, RN</last_name>
    <email>cvcrc5@amc.seoul.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Mid America Heart Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gregg W Stone, MD</last_name>
      <email>gstone@crf.org</email>
    </contact>
    <investigator>
      <last_name>Gregg W Stone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern Hospital , Victoria Australia</name>
      <address>
        <city>Epping</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Eastern Heart Clinic, Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>EMO Centro Cuore Columbus, San Raffaele Hospital</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Aichi Medical University</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Kawasaki Medical School</name>
      <address>
        <city>Kurashiki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takeshi Kimura, MD</last_name>
      <email>taketaka@kuhp.kyoto-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Takeshi Kimura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wakayama Medical University</name>
      <address>
        <city>Wakayama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung-jung Park, MD, PhD</last_name>
      <email>sjpark@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Seung-jung Park, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun-Sook Kim, MD</last_name>
      <email>heartsk@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Hyun-Sook Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Gangwon National Univ. Hospital</name>
      <address>
        <city>Chuncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bong-Ki Lee, MD</last_name>
      <email>mdbklee@kangwon.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Bong-Ki Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang-Wook Nam, MD</last_name>
      <email>ncwcv@dsmc.or.kr</email>
    </contact>
    <investigator>
      <last_name>Chang-Wook Nam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Si-Wan Choi, MD</last_name>
      <email>siwanc@cnu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Si-wan Choi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Daejeon ST. Mary's Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung-Ho Her, MD</last_name>
      <phone>82-042-220-9686</phone>
      <email>hhhsungho@naver.com</email>
    </contact>
    <investigator>
      <last_name>Sung-Ho Her, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Keun Ahn, MD</last_name>
      <email>cecilyk@chonnam.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Young-Keun Ahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>ChonBuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Dong-A Medical Center</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moo-Hyun Kim, MD</last_name>
      <email>kmh60@damc.or.kr</email>
    </contact>
    <investigator>
      <last_name>Moo-Hyun Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bon-Kwon Koo, MD</last_name>
      <email>bkkoo@snu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Bundang Cha Medical Center</name>
      <address>
        <city>Sŏngnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Won-jang Kim, MD</last_name>
      <email>mdwjkim@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Won-jang Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang hospital</name>
      <address>
        <city>Sŏngnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>In-Ho Chae, MD</last_name>
      <email>ihchae@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>In-Ho Chae, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital and Canterbury DHB, University of Otago</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Smyth, MD</last_name>
      <email>david.smyth@cdhb.health.nz</email>
    </contact>
    <investigator>
      <last_name>David Smyth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National University Heart Center</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Hsien Li Kao, MD</last_name>
      <email>hsienli_kao@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Paul Hsien Li Kao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>China</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>December 1, 2014</study_first_submitted>
  <study_first_submitted_qc>December 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2014</study_first_posted>
  <last_update_submitted>July 16, 2019</last_update_submitted>
  <last_update_submitted_qc>July 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Seung-Jung Park</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <keyword>coronary intervention</keyword>
  <keyword>Vulnerable Plaque</keyword>
  <keyword>Insignificant Stenosis</keyword>
  <keyword>Bioresorbable Vascular Scaffold</keyword>
  <keyword>Everolimus Eluting stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

